메뉴 건너뛰기




Volumn 75, Issue 11, 2016, Pages 1979-1983

Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: Clinical and MRI findings

Author keywords

DMARDs (biologic); Magnetic Resonance Imaging; Rheumatoid Arthritis

Indexed keywords

C REACTIVE PROTEIN; DECERNOTINIB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; PLACEBO; 2-((2-(1H-PYRROLO(2,3-B)PYRIDIN-3-YL)PYRIMIDIN-4-YL)AMINO)-2-METHYL-N-(2,2,2-TRIFLUOROETHYL)BUTANAMIDE; ANTIRHEUMATIC AGENT; FUSED HETEROCYCLIC RINGS; VALINE;

EID: 84964765486     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-208901     Document Type: Article
Times cited : (41)

References (17)
  • 2
    • 31144460322 scopus 로고    scopus 로고
    • Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: Unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis
    • Walker JG, Ahern MJ, Coleman M, et al. Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis. Ann Rheum Dis 2006;65:149-56.
    • (2006) Ann Rheum Dis , vol.65 , pp. 149-156
    • Walker, J.G.1    Ahern, M.J.2    Coleman, M.3
  • 3
    • 0028206119 scopus 로고
    • JAK3: A novel JAK kinase associated with terminal differentiation of hematopoietic cells
    • Rane SG, Reddy EP. JAK3: A novel JAK kinase associated with terminal differentiation of hematopoietic cells. Oncogene 1994;9:2415-23.
    • (1994) Oncogene , vol.9 , pp. 2415-2423
    • Rane, S.G.1    Reddy, E.P.2
  • 4
    • 0031919849 scopus 로고    scopus 로고
    • Jaks and STATs: Biological implications
    • Leonard WJ, OShea JJ. Jaks and STATs: biological implications. Annu Rev Immunol 1998;16:293-322.
    • (1998) Annu Rev Immunol , vol.16 , pp. 293-322
    • Leonard, W.J.1    Oshea, J.J.2
  • 5
    • 84881119287 scopus 로고    scopus 로고
    • Early MRI measures independently predict 1-year and 2-year radiographic progression in rheumatoid arthritis: Secondary analysis from a large clinical trial
    • Baker JF, Ostergaard M, Emery P, et al. Early MRI measures independently predict 1-year and 2-year radiographic progression in rheumatoid arthritis: secondary analysis from a large clinical trial. Ann Rheum Dis 2014;73:1968-74.
    • (2014) Ann Rheum Dis , vol.73 , pp. 1968-1974
    • Baker, J.F.1    Ostergaard, M.2    Emery, P.3
  • 6
    • 45349090842 scopus 로고    scopus 로고
    • Magnetic resonance imaging findings in 84 patients with early rheumatoid arthritis: Bone marrow oedema predicts erosive progression
    • Haavardsholm EA, Bøyesen P, Østergaard M, et al. Magnetic resonance imaging findings in 84 patients with early rheumatoid arthritis: bone marrow oedema predicts erosive progression. Ann Rheum Dis 2008;67:794-800.
    • (2008) Ann Rheum Dis , vol.67 , pp. 794-800
    • Haavardsholm, E.A.1    Bøyesen, P.2    Østergaard, M.3
  • 7
    • 61549139043 scopus 로고    scopus 로고
    • MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis Results from a 2-year randomised controlled trial (CIMESTRA)
    • Hetland ML, Ejbjerg B, Hørslev-Petersen K, et al. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA). Ann Rheum Dis 2009;68:384-90.
    • (2009) Ann Rheum Dis , vol.68 , pp. 384-390
    • Hetland, M.L.1    Ejbjerg, B.2    Hørslev-Petersen, K.3
  • 8
    • 84893583879 scopus 로고    scopus 로고
    • The OMERACT-RAMRIS rheumatoid arthritis magnetic resonance imaging joint space narrowing score: Intrareader and interreader reliability and agreement with computed tomography and conventional radiography
    • Døhn UM, Conaghan PG, Eshed I, et al. The OMERACT-RAMRIS rheumatoid arthritis magnetic resonance imaging joint space narrowing score: intrareader and interreader reliability and agreement with computed tomography and conventional radiography. J Rheumatol 2014;41:392-7.
    • (2014) J Rheumatol , vol.41 , pp. 392-397
    • Døhn, U.M.1    Conaghan, P.G.2    Eshed, I.3
  • 9
    • 84971329257 scopus 로고    scopus 로고
    • Validity of early MRI structural damage end points and potential impact on clinical trial design in rheumatoid arthritis
    • Baker JF, Conaghan PG, Emery P, et al. Validity of early MRI structural damage end points and potential impact on clinical trial design in rheumatoid arthritis. Ann Rheum Dis 2016;75:1114-9.
    • Ann Rheum Dis , vol.2016 , Issue.75 , pp. 1114-1119
    • Baker, J.F.1    Conaghan, P.G.2    Emery, P.3
  • 10
    • 84922808076 scopus 로고    scopus 로고
    • A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis
    • Fleischmann RM, Damjanov NS, Kivitz AJ, et al. A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis. Arthritis Rheumatol 2015;67:334-43.
    • (2015) Arthritis Rheumatol , vol.67 , pp. 334-343
    • Fleischmann, R.M.1    Damjanov, N.S.2    Kivitz, A.J.3
  • 11
    • 84952050201 scopus 로고    scopus 로고
    • VX-509 (decernotinib), an oral selective JAK-3 inhibitor, in combination with methotrexate in patients with rheumatoid arthritis
    • Genovese MC, van Vollenhoven RF, Pacheco-Tena C, et al. VX-509 (decernotinib), an oral selective JAK-3 inhibitor, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheumatol 2016;68:46-55.
    • Arthritis Rheumatol , vol.2016 , Issue.68 , pp. 46-55
    • Genovese, M.C.1    Van Vollenhoven, R.F.2    Pacheco-Tena, C.3
  • 12
    • 19944430372 scopus 로고    scopus 로고
    • An introduction to the EULAR-OMERACT rheumatoid arthritis MRI reference image Atlas
    • Østergaard M, Edmonds J, McQueen F, et al. An introduction to the EULAR-OMERACT rheumatoid arthritis MRI reference image Atlas. Ann Rheum Dis 2005;64(Suppl 1):i3-7.
    • (2005) Ann Rheum Dis , vol.64 , pp. i3-7
    • Østergaard, M.1    Edmonds, J.2    McQueen, F.3
  • 13
    • 84880206715 scopus 로고    scopus 로고
    • Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: The ASSET randomised controlled trial
    • Conaghan PG, Durez P, Alten RE, et al. Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: The ASSET randomised controlled trial. Ann Rheum Dis 2013;72:1287-94.
    • (2013) Ann Rheum Dis , vol.72 , pp. 1287-1294
    • Conaghan, P.G.1    Durez, P.2    Alten, R.E.3
  • 14
    • 80053563603 scopus 로고    scopus 로고
    • Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: Results of the GO-FORWARD trial
    • Conaghan PG, Emery P, Østergaard M, et al. Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial. Ann Rheum Dis 2011;70:1968-74.
    • (2011) Ann Rheum Dis , vol.70 , pp. 1968-1974
    • Conaghan, P.G.1    Emery, P.2    Østergaard, M.3
  • 15
    • 84897983379 scopus 로고    scopus 로고
    • The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: Results from the ACT-RAY MRI substudy
    • Conaghan PG, Peterfy C, Olech E, et al. The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy. Ann Rheum Dis 2014;73:810-16.
    • (2014) Ann Rheum Dis , vol.73 , pp. 810-816
    • Conaghan, P.G.1    Peterfy, C.2    Olech, E.3
  • 16
    • 84933074076 scopus 로고    scopus 로고
    • MRI assessment of early response to certolizumab pegol in rheumatoid arthritis: A randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0 1, 2, 4, 8 and 16
    • Østergaard M, Jacobsson LT, Schaufelberger C, et al. MRI assessment of early response to certolizumab pegol in rheumatoid arthritis: A randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16. Ann Rheum Dis 2015;74:1156-63.
    • (2015) Ann Rheum Dis , vol.74 , pp. 1156-1163
    • Østergaard, M.1    Jacobsson, L.T.2    Schaufelberger, C.3
  • 17
    • 84954208482 scopus 로고    scopus 로고
    • MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: Results from the randomised, placebo-controlled, double-blind RA-SCORE study
    • Peterfy C, Emery P, Tak PP, et al. MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study. Ann Rheum Dis 2016;75:170-7.
    • (2016) Ann Rheum Dis , vol.75 , pp. 170-177
    • Peterfy, C.1    Emery, P.2    Tak, P.P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.